In a multi-million-dollar investment, Schott has opened a new manufacturing facility in Arizona, US to serve the diagnostics market.
Schott has opened its first facility in US to expand the development and manufacturing of diagnostics and life science consumables.
The facility in Phoenix will increase production capabilities to get microfluidic products to the market faster and more efficiently.
The approx. 40,000 sq ft facility comprises of clean room, and will manufacture a high volume of microarrays and microfluidic devices.
This will allow the company to onshore manufacturing to secure domestic supply chains.
Over several years, the facility will create 150 jobs in the greater Phoenix area, growing Schott Minifab’s employee base in Phoenix by 300%.
The opening event on January 9, 2023, saw attendees from Schott, the state, local government officials, and prominent members of the Phoenix biotech community.
Dr Heinz Kaiser, a member of Schott’s management board, said: “The United States is one of our most important markets, and we are pleased to expand our R&D and production facilities in this region.
“Enhancing our global footprint with a manufacturing base in Phoenix not only expands our reach, but also caters to the fast-growing and dynamic diagnostics market in North America. We are eager to build a unique pipeline for this market in the US.”
Phoenix will mark Schott’s third diagnostics location, with other centres of excellence located in Jena, Germany, and Melbourne, Australia.